LATEST UPDATES » Vol 22, No 06, June 2018 – Cancer - Therapies and strategies for better patient outcomes       » Gardasil 9 supply running short in Hong Kong       » China helps Tajikistan tackle grassland degradation       » Immuno-oncology trials in China surge more than 50 per cent       » Yeast for industrial biotechnology       » Uncontrolled hypertension in rural communities      
Commencement of BIT225 Phase 2 HIV-1 Clinical Trial

Sydney, AUSTRALIA — The Directors of Biotron Limited are pleased to announce that the Company has commenced a Phase 2 human clinical trial (BIT225-009) with its lead antiviral drug BIT225.

The trial is a Phase 2, multi-centre, randomised, placebo-controlled, double-blind study of BIT225 and Combination Antiretroviral Therapy (cART): Atripla® in patients with Human Immunodeficiency Virus (HIV-1) infection. HIV-1-infected patients will not have previously been on anti-HIV-1 treatment (i.e. treatment naïve) and who will be commencing a cART regimen (approved anti-HIV-1 drugs). Patients will receive cART in addition to 12 weeks with BIT225 or placebo.

The trial includes a dose escalation, with an initial group of 9 patients receiving 100 mg BIT225 once daily, or placebo, together with cART. A second group of 27 patients will receive 200 mg BIT225 once daily, or placebo, together with cART.

At the conclusion of the trial, patients will remain on cART as per standard treatment protocols.

The trial will be undertaken at HIV-NAT, Thai Red Cross AIDS Research Centre in Bangkok, Thailand. HIV-NAT is affiliated with the Kirby Institute for Infection and Immunity in Society located at the University of New South Wales (UNSW), Sydney, Australia, and with the Amsterdam Institute for Global Health and Development in Amsterdam (AIGHD), The Netherlands. HIV-NAT is an internationally recognised research organisation and its core research areas include pharmacokinetics of HIV-1 therapy, co-infections with Hepatitis B, tuberculosis and HPV, new drug development and strategic studies.

An additional trial site is expected to commence recruitment shortly once appropriate ethics and regulatory approvals are in place at that second site.

The primary objectives of the study are to:

  • Determine the efficacy of 12 weeks of BIT2 25 treatment in HIV-1 infected subjects receiving cART: Atripla® by measuring plasma viral load decay and modelling HIV-1 decay.
  • Determine the safety and tolerability of BIT225 administered once daily for 12 weeks in HIV-1 infected subjects on cART: Atripla®.

The secondary objectives of this study are to:

  • Determine if 12 weeks of BIT225 treatment in addition to cART: At ripla® will impact levels of sCD163, a primary biomarker of monocyte immune activation.
  • Evaluate the pharmacokinetics of 100 mg BIT225 administered once daily for 12 weeks in combination with cART: Atripla® in subjects infected with HIV-1.

The Company is aiming to demonstrate:

  • Accelerated reduction of HIV-1 in patients treated with BIT225 in combination with cART, indicating that BIT225 can significantly improve current standard of care anti-HIV-1 treatment; and
  • Reduction in HIV-1-induced immune activation, indicating that BIT225 is targeting viral reservoirs not impacted by cART.

The commencement of the BIT225-009 clinical trial builds on the recent announcement by Biotron of successful results with BIT225 in a humanised mouse study of HIV-1 infection.

Biotron’s Managing Director, Dr. Michelle Miller said, “Initiating this clinical trial is an important step towards demonstrating the clinical benefit that BIT225 could bring to the treatment of HIV-1. BIT225 has the potential to play a key role in the eradication of HIV-1 by targeting and clearing HIV-1 from cellular reservoirs. We expect to see early results from the trial in late Q3 this year.”

Source: Biotron Ltd. & Monsoon Comms

Click here for the complete issue.

news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
Asia Pacific Biotech News
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
Obesity / Outlook for 2018
Searching for the fountain of youth
Women in Science - Making a difference
Digestive health in the 21st century - Trust your guts
Dental health - The root to good health
Cancer - Therapies and strategies for better patient outcomes
Water management / Vaccination
Regenerative medicine / Biotech start ups
Digital healthcare / 3D printing
Bones / Breast cancer
Liver health / Top science research nations & institutions
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy